Stem cell mobilization and transplantation
| . | VDCR n = 48 . | VDR n = 42 . | VDC n = 33 . | VDC-mod n = 17 . |
|---|---|---|---|---|
| Stem cell mobilization | ||||
| Patients undergoing stem cell mobilization with data available, n (%) | 25 (50) | 26 (62) | 14 (42) | 10 (59) |
| Median CD34+ cell yield, × 106/kg, n (range) | 6.8 (0.3-21) | 7.8 (2.2-25.9) | 7.95 (3.1-17.6) | 7.75 (2.1-20) |
| Patients with < 2.5 × 106/kg CD34+ cells during first attempt, n (%)* | 4 (8) | 3 (7) | 0 | 2 (12) |
| Stem cell transplantation | ||||
| Patients undergoing ASCT with data available, n (%) | 20 (42) | 19 (45) | 10 (30) | 10 (59) |
| Median time to recovery of ANC > 500 cells/mm3, d (range) | 11 (7-15) | 11 (0-13) | 11 (0-16) | 11 (0-13) |
| Median time to recovery of platelets > 20 000 cells/mm3, d (range) | 12 (0-37) | 10.5 (0-21) | 11.5 (0-31) | 10 (0-23) |
| . | VDCR n = 48 . | VDR n = 42 . | VDC n = 33 . | VDC-mod n = 17 . |
|---|---|---|---|---|
| Stem cell mobilization | ||||
| Patients undergoing stem cell mobilization with data available, n (%) | 25 (50) | 26 (62) | 14 (42) | 10 (59) |
| Median CD34+ cell yield, × 106/kg, n (range) | 6.8 (0.3-21) | 7.8 (2.2-25.9) | 7.95 (3.1-17.6) | 7.75 (2.1-20) |
| Patients with < 2.5 × 106/kg CD34+ cells during first attempt, n (%)* | 4 (8) | 3 (7) | 0 | 2 (12) |
| Stem cell transplantation | ||||
| Patients undergoing ASCT with data available, n (%) | 20 (42) | 19 (45) | 10 (30) | 10 (59) |
| Median time to recovery of ANC > 500 cells/mm3, d (range) | 11 (7-15) | 11 (0-13) | 11 (0-16) | 11 (0-13) |
| Median time to recovery of platelets > 20 000 cells/mm3, d (range) | 12 (0-37) | 10.5 (0-21) | 11.5 (0-31) | 10 (0-23) |
V indicates bortezomib; D, dexamethasone; R, lenalidomide; C, cyclophosphamide; VDC-mod, VDC plus a day 15 dose of C; ANC, absolute neutrophil count; and ASCT, autologous stem cell transplantation.
At second mobilization attempt, 5 patients received cyclophosphamide + G-CSF and 2 patients (both VDR arm) received plerixafor + G-CSF.